Colorectal Cancer News

New Phase II Trial Uses Drug Combination for Colorectal Cancer Patients with Liver Metastases

This new phase II trial therapy aims to combine two standard treatments to attempt to shrink liver metastases that are too large to be removed surgically (unresectable), with a goal of making them easier to remove. This trial uses FOLFOXIRI, which has had successful results in colon cancer patients with liver metastases, and combines it with panitumumab, an antibody that targets a protein involved in cell growth called the epidermal growth factor receptor (EGFR). Panitumumab is already approved for patients with metastatic colorectal cancer in second line, although it has historically been more successful for patients with liver metastases that can be surgically removed. To be eligible for this trial, patients will need to have a normal (wild-type) KRAS tumor marker.

To learn if you are eligible for this study, call the CCA’s Clinical Trial Matching Service at (866) 278-0392 to talk to a patient navigator.

Return